Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Liabilities (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Total Liabilities data on record, last reported at $134.2 million in Q4 2025.

  • For Q4 2025, Total Liabilities rose 22.21% year-over-year to $134.2 million; the TTM value through Dec 2025 reached $134.2 million, up 22.21%, while the annual FY2025 figure was $134.2 million, 22.21% up from the prior year.
  • Total Liabilities reached $134.2 million in Q4 2025 per CRNX's latest filing, up from $123.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $134.2 million in Q4 2025 and bottomed at $14.1 million in Q1 2021.
  • Average Total Liabilities over 5 years is $68.4 million, with a median of $66.5 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: decreased 8.91% in 2021, then surged 206.48% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $19.1 million in 2021, then soared by 87.97% to $35.8 million in 2022, then soared by 168.49% to $96.2 million in 2023, then grew by 14.07% to $109.8 million in 2024, then increased by 22.21% to $134.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $134.2 million in Q4 2025, $123.9 million in Q3 2025, and $118.0 million in Q2 2025.